19.73
Schlusskurs vom Vortag:
$20.94
Offen:
$20.97
24-Stunden-Volumen:
271.12K
Relative Volume:
1.24
Marktkapitalisierung:
$352.58M
Einnahmen:
$116.88M
Nettoeinkommen (Verlust:
$-25.09M
KGV:
-140.93
EPS:
-0.14
Netto-Cashflow:
$-20.74M
1W Leistung:
-0.05%
1M Leistung:
+11.22%
6M Leistung:
-24.23%
1J Leistung:
+113.90%
Rigel Pharmaceuticals Stock (RIGL) Company Profile
Firmenname
Rigel Pharmaceuticals
Sektor
Branche
Telefon
650-624-1100
Adresse
611 GATEWAY BOULEVARD, SUITE 900, SOUTH SAN FRANCISCO, CA
Vergleichen Sie RIGL mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
RIGL
Rigel Pharmaceuticals
|
19.73 | 352.80M | 116.88M | -25.09M | -20.74M | -0.14 |
![]()
ONC
Beigene Ltd Adr
|
238.76 | 24.41B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
434.03 | 111.55B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.2548 | 42.47M | 0 | 0 | 0 | 0.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
596.85 | 63.16B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
VRNA
Verona Pharma Plc Adr
|
72.69 | 5.92B | 0 | -153.72M | -103.81M | -2.00 |
Rigel Pharmaceuticals Stock (RIGL) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2023-04-03 | Fortgesetzt | Piper Sandler | Neutral |
2022-06-09 | Herabstufung | Citigroup | Buy → Neutral |
2022-06-08 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2022-06-08 | Herabstufung | Piper Sandler | Overweight → Neutral |
2022-03-23 | Eingeleitet | B. Riley Securities | Neutral |
2020-11-09 | Herabstufung | JP Morgan | Overweight → Neutral |
2019-11-15 | Fortgesetzt | Cantor Fitzgerald | Overweight |
2019-09-26 | Fortgesetzt | JP Morgan | Overweight |
2019-03-01 | Bestätigt | Cantor Fitzgerald | Overweight |
2018-08-27 | Eingeleitet | Citigroup | Buy |
2018-05-02 | Bestätigt | Cantor Fitzgerald | Overweight |
2017-12-21 | Fortgesetzt | Piper Jaffray | Overweight |
2017-12-15 | Eingeleitet | Cantor Fitzgerald | Overweight |
2017-11-06 | Fortgesetzt | H.C. Wainwright | Buy |
2017-03-09 | Bestätigt | H.C. Wainwright | Buy |
2016-08-31 | Bestätigt | H.C. Wainwright | Buy |
2016-08-30 | Bestätigt | Piper Jaffray | Overweight |
2016-07-13 | Eingeleitet | H.C. Wainwright | Buy |
2016-06-13 | Eingeleitet | Piper Jaffray | Overweight |
2016-04-22 | Hochstufung | JP Morgan | Neutral → Overweight |
2013-04-08 | Bestätigt | Stifel | Buy |
2012-11-29 | Eingeleitet | UBS | Neutral |
2012-11-06 | Bestätigt | Oppenheimer | Outperform |
2012-03-26 | Eingeleitet | Canaccord Genuity | Hold |
2010-12-10 | Herabstufung | MP Advisors | Outperform → Market Perform |
Alle ansehen
Rigel Pharmaceuticals Aktie (RIGL) Neueste Nachrichten
Rigel Announces Poster Presentations at the 2025 ASCO Annual Meeting and EHA2025 Congress - PR Newswire
17,123 Shares in Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Acquired by Dimensional Fund Advisors LP - Defense World
(RIGL) Investment Analysis - news.stocktradersdaily.com
Rigel Pharmaceuticals, Inc.'s (NASDAQ:RIGL) CEO Compensation Looks Acceptable To Us And Here's Why - simplywall.st
Here's Why Rigel (RIGL) Is a Great 'Buy the Bottom' Stock Now - Yahoo Finance
Is Rigel Pharmaceuticals (RIGL) a Great Value Stock Right Now? - Yahoo Finance
Wall Street Analysts Think Rigel (RIGL) Could Surge 82.3%: Read This Before Placing a Bet - MSN
Upgrade: Analysts Just Made A Captivating Increase To Their Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Forecasts - Yahoo Finance
Wells Fargo & Company MN Buys 2,648 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Cantor Fitzgerald Brokers Reduce Earnings Estimates for RIGL - Defense World
B. Riley Expects Reduced Earnings for Rigel Pharmaceuticals - Defense World
Earnings Estimates Rising for Rigel (RIGL): Will It Gain? - Yahoo Finance
MetLife Investment Management LLC Acquires 2,014 Shares of Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) - Defense World
Rigel Pharmaceuticals, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Predictions - simplywall.st
Rigel pharmaceuticals targets $200M-$210M revenue in 2025 with strong Q1 performance - MSN
Rigel Pharmaceuticals, Inc. Just Recorded A 370% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
HC Wainwright Issues Positive Outlook for RIGL Earnings - Defense World
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Q1 2025 Earnings Call Transcript - Insider Monkey
Rigel Pharmaceuticals First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Rigel Pharmaceuticals, Inc. (NASDAQ:RIGL) Given Average Rating of “Hold” by Analysts - Defense World
Rigel Pharmaceuticals Reports Strong Growth and Strategic Advances - TipRanks
Rigel Pharmaceuticals: Q1 Earnings Showcase Growing Momentum (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals (RIGL) Price Target Raised by Cantor Fitzg - GuruFocus
Earnings call transcript: Rigel Pharmaceuticals sees stock surge after Q1 2025 earnings - Investing.com Nigeria
Jefferies cuts Rigel stock target to $20.45, maintains hold - Investing.com
Earnings call transcript: Rigel Pharmaceuticals sees stock surge after Q1 2025 earnings By Investing.com - Investing.com South Africa
Rigel Pharma Jump 9.9% Premarket; Guides 'Positive' Net Income in 2025 After Swinging to Profit in Q1 - marketscreener.com
Rigel Pharmaceuticals Inc (RIGL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... By GuruFocus - Investing.com Canada
Rigel Pharmaceuticals Inc (RIGL) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Rigel Pharmaceuticals Inc (RIGL) Q1 2025 Earnings Call Highlight - GuruFocus
Rigel Pharmaceuticals Reports Strong Q1 2025 Earnings - TipRanks
Rigel: Q1 Earnings Snapshot - CTPost
Rigel Pharmaceuticals, Inc. 2025 Q1ResultsEarnings Call Presentation (NASDAQ:RIGL) - Seeking Alpha
Rigel Pharmaceuticals reports Q1 EPS 63c vs. 47c last year - TipRanks
Rigel Pharmaceuticals reaffirms FY25 revenue $200M-$210M, consensus $197.79M - TipRanks
Rigel Pharmaceuticals (RIGL) Surpasses Q1 Revenue Expectations | - GuruFocus
Rigel Pharmaceuticals Inc Surpasses Q1 2025 Estimates with $0.64 EPS and $53.3 Million Revenue - GuruFocus
Rigel Pharmaceuticals (RIGL) Beats Q1 Earnings and Revenue Estimates - Yahoo Finance
RIGL Projects Strong Financial Outlook for FY25 | RIGL Stock New - GuruFocus
Rigel Pharmaceuticals Inc reports results for the quarter ended March 31Earnings Summary - TradingView
RIGL Projects Strong Financial Outlook for FY25 | RIGL Stock News - GuruFocus
Rigel Reports First Quarter 2025 Financial Results and Provides Business Update - Longview News-Journal
Rigel Pharmaceuticals Q1 25 Earnings Conference Call AT 4:30 PM ET - Nasdaq
Rigel Pharmaceuticals Inc (RIGL) Q1 2025 Earnings Report Preview: What To Expect - GuruFocus
Rigel Announces Conference Call and Webcast to Report First Quarter 2025 Financial Results and Business Update - Kilgore News Herald
Rigel Announces Conference Call and Webcast to Report First Quar - GuruFocus
Rigel Pharmaceuticals Sets Key Q1 2025 Earnings Date: How to Access Latest Biotech Results - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Finanzdaten der Rigel Pharmaceuticals-Aktie (RIGL)
Umsatz
Nettogewinn
Free Cashflow
ENV
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):